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A B S T R A C T
A rapid, simple and sensitive ultra-high performance liquid chromatography–tandem mass
spectrometric (UPLC–MS/MS) method was developed and validated for the determination
of hederasaponin B, an active triterpenoid saponin widely existed in Hedera helix L. Plasma
samples were processed by protein precipitation with acetonitrile and separated on a Thermo
Hypersil GOLD C18 (2.1 mm × 50 mm,1.9 μm) at flow rate of 0.3 ml/min, with a gradient elution
consisting of acetonitrile and water containing 0.1% (v/v) formic acid at 30 °C and detected
by electrospray ionization mass spectrometry in the positive multiple reaction monitoring
(MRM) mode. The linearity was found to be within the concentration range of 0.5–5000 ng/
ml with a lower limit of quantification of 0.5 ng/ml. The absolute oral bioavailability of
hederasaponin B was 0.24 ± 0.49%. This indicated that the concentration-time course of the
hederasaponin B existed a double-peak phenomenon. This method was further applied to
the determination of hederasaponin B in rat plasma and showed good practicability, for the
first time, after intragastric (25 mg/kg) and intravenous (2 mg/kg) administration in rats.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Hedera helix L., an important herbal medicine, is an evergreen
cirrus belonging to the family of Araliaceae. In addition to land-
scaping and greening, the leaf extractions had been reported
to have anti-inflammatory [1,2], anti-fungal [3], anthelmintic
[4], anti-bronchial [5] properties and increased β2-adrenegic re-
sponsiveness [6,7] activity. Phytochemical investigations revealed
that triterpene saponins were primary active components of
H. helix [8,9]. As we all know, triterpene saponins in Araliaceae
played an important role in the aspect of anti-inflammation
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and anti-cancer. Hederasaponin B as a member of this kind
of active triterpene saponins had drawn increasing atten-
tion, especially effective in anti-cancer, anti-inflammation and
anti-virus fields. Recently, Lin-Tao Han determined that five
triterpenoid saponins isolated from Anemone flaccid including
hederasaponin B could induce apoptosis activity in Hela cells
[10]. It was also reported that the expressions of EV71C3 and
C4aVP protein were inhibited in the presence of 50 μg/ml
hederasaponin B, which had significant anti-viral effects on
hand, foot and mouth disease (HFMD) [11]. According to Liu’s
work, hederasaponin B decreased pro-inflammatory cytokine
levels and significantly inhibited TNF-α and IL-6 production in
LPS-treated RAW264.7 cells [12]. In addition, the superoxide gen-
eration induced by arachidonic acid (AA) was suppressed by
hederasaponin B effectively [13]. In consideration of numer-
ous bioactivities of hederasaponin B above, it is essential to
understand the pharmacokinetic and bioavailability charac-
teristics. To develop a validated analytical method suitable for
hederasaponin B determination in relevant biological samples
is now an urgent task.
Therefore, a simple and reliable method for pharmacoki-
netic study of hederasaponin B is badly in need to understand
the drug safety profiles and interpret the mechanism of ef-
fectiveness and toxicity. However, in the past decades,
researchers paid more attention to the quantity or quality of
components in H. helix [14–16]. Only few literatures demon-
strated the pharmacokinetic mechanism of the active
ingredients such as α-hederin [17], hederacoside C [18]. Un-
fortunately, we found no information about pharmacokinetic
study of hederasaponin B. Thus, a novel, sensitive and simple
ultra-high performance liquid chromatography tandem mass
spectrometry (UPLC–MS/MS) method in MRM mode was de-
veloped for determination of hederasaponin B in plasma, and
pharmacokinetic studies were devised to determine its
bioavailability in rats, for the first time. It was expected that
the results of this work would provide some references for the
apprehension of the action mechanism and further clinical ef-
ficacy studies of hederasaponin B.
2. Experimental
2.1. Materials, reagents and animals
Hederasaponin B and hederacoside D (IS) were purchased from
spring & autumn biological engineering Co. Ltd. (Nangjing,
China). Acetonitrile of HPLC grade was obtained from Fisher
Scientific (Pittsburgh, PA, USA). Deionized water was purified
using a Milli-Q system (Millipore, Milford, MA, USA). All the other
reagents were of analytical grade.
SPF degree Sprague Dawley rats (male, 200 ± 20 g) were pro-
vided by Experimental Animal Center of Shenyang
Pharmaceutical University (Shenyang, China).They were housed
in controlled conditions (temperature, 22 ± 2 °C; humidity
50 ± 10%; 12 h light/dark cycle) and received a standard rat chow
and tap watered ad libitum for a week prior to experiments.
All animal experiments were carried out according to the Guide-
lines for Animal Experimentation of Shenyang Pharmaceutical
University; the procedure was approved by the Animal Ethics
Committee of the institute.
2.2. Instruments and conditions
The UPLC–MS/MS analysis was carried out on an Acquity UPLC-
Class system (Waters Corp., Milford, MA, USA) coupled with a
Xevo TQ-S mass spectrometer (Waters Corp., Milford, MA, USA).
A Thermo Hypersil GOLD C18 (2.1 mm × 50 mm, 1.9 μm) was em-
ployed and the column temperature was maintained at 30 °C.
Gradient elution (delivered at 0.3 ml/min) was employed using
acetonitrile (mobile phase A) and 0.1% formic acid in water
(mobile phase B). The gradient started at 20% A, followed by
linear increased to 60% A from 0 to 3 min, then quickly re-
turned to initial 20% A and maintained till 4 min for column
balance. The auto-sampler was conditioned at 4 °C and the in-
jection volume was 2 μl.
A mass spectrometer with an electrospray ionization (ESI)
interface in a positive ion mode (ESI) was used for quantita-
tive analysis. The capillary voltage was set at 3.0 kV, and the
source and desolvation temperatures were set at 150 °C and
350 °C respectively. Nitrogen was used as the desolvation and
cone gas with a flow rate of 700 and 60 l/h. The quantifica-
tion was performed using multiple reaction monitoring (MRM)
of the transitions of m/z 1227.27→492.77 for hederasaponin B,
and m/z 1097.48 → 493.75 for hederacoside D (IS), respec-
tively. The results were shown in Table 1 and Fig. 1.
2.3. Sample pretreatment
A simple and rapid protein precipitation method was used for
the preparation of plasma samples. An aliquot of 100 μl of each
plasma was spiked with 10 μl of IS (2 μg/ml) and mixed for 30 s.
Then, 300 μl of acetonitril was added, and the mixture was
vortexed for 1 min. After centrifugation at 12,000 rpm for 10 min,
the supernatant was transferred to a tube and evaporated to
dryness at 40 °C under a slight stream of nitrogen. Then, the
residue was reconstituted with 100 μl of mobile phase, and a
2 μl aliquot of the supernatant was injected into the UPLC-
MS/MS for analysis after centrifugation at 12,000 rpm for 5 min.
2.4. Preparation of calibration standards and quality
control (QC) samples
Stock solutions of hederasaponin B and IS were prepared in
methanol at 1.0 mg/ml and 100 μg/ml, respectively. The stan-
dard stock solution was then serially diluted with methanol
to obtain working standard solutions in a concentration range
of 5–50,000 ng/ml, for hederasaponin B.The IS solution was simi-
larly diluted to 2 μg/ml with methanol. Calibration standard
samples of hederasaponin B were obtained by spiking 10 μl of
the appropriate working solutions to 100 μl blank plasma.
Quality control (QC) samples at low, medium and high
Table 1 – MRM transition in positive ion mode cone
voltage and collision energy for the determination of the
hederasaponin B and IS.
Analytes Transition Cone
voltage(V)
Collision
energy (eV)
Hederasaponin B 1227.27→492.87 60 58
Hederacoside D 1097.48→492.75 55 58
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concentrations (1, 100 and 4000 ng/ml) were prepared sepa-
rately in the same fashion. All stock solutions, working solutions
and quality control samples were stored at −20 °C until used.
2.5. Method validation
2.5.1. Specificity
Specificity of this method was determined by comparing chro-
matograms of blank plasma from six different rats, blank
plasma spiked with hederasaponin B and IS, and plasma
samples obtained after administration of hederasaponin B.
2.5.2. Linearity and LLOQ
Calibration curves were constructed using 8 calibration stan-
dards over the range of 0.5–5000 ng/ml by plotting the peak area
ratio of hederasaponin B to the IS (y) versus the nominal con-
centrations of hederasaponin B (x) in plasma.The linearity was
assessed using a weighted (1/x2) least square regression. The
criteria for the calibration curve included a correlation coef-
ficient (r) of >0.99.The lower limit of quantification (LLOQ) which
the signal-to-noise ratio was determined to be more than 10
(S/N > 10) was defined as the reproducible lowest possible drug
concentration that could be determined with both accuracy and
precision within ±20% .
2.5.3. Extraction recovery and matrix effect
The recovery was determined at three QC levels with six rep-
licates by comparing the peak areas from plasma samples
spiked before extraction with those spiked after extraction.The
matrix effect was determined by examining the ratio of the
peak areas dissolved in the blank matrix extract to that in stan-
dard solution containing equivalent amounts of the compounds.
The procedure was repeated 6 times.
2.5.4. Precision and accuracy
The precision and accuracy of the method were assessed by
performing 6 replicates of QC samples spiked with low, medium
and high concentrations against calibration standards on the
Fig. 1 – MS/MS spectra of hederasaponin B(A) and hederacoside D (IS) (B).
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same day and on 3 consecutive days. The precision at each QC
concentration was expressed as relative standard deviation
(RSD%) and the accuracy as error (RE%).
2.5.5. Stability
The stability tests of analytes in rat plasma were under dif-
ferent storage conditions: 6 h at room temperature, under
autosampler condition (4 °C) for 12 h, frozen for 2 weeks and
three freeze-thaw cycles. All stability testing QC samples were
determined by using a calibration curve of freshly prepared
standards. The results were evaluated by RE% and RSD%.
2.6. Pharmacokinetic study
10 male Sprague Dawley (SD) rats with free access to food and
water, then, fasted for 12 h prior to experiments were ran-
domly divided into two groups with 5 in each. The
hederasaponin B was prepared in normal saline solution. The
method was applied to the pharmacokinetic studies of
hederasaponin B by two different administrations: intrave-
nous (2.0 mg/kg) and intragastric (25 mg/kg). Blood samples
(about 0.3 ml) were collected in heparinized tubes via the post-
orbital venous plexus veins from each rat at 0 (pre-dose), 0.083,
0.167, 0.25, 0.3, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24 and 36 h after
intragastric administration and at 0, 0.05, 0.083, 0.167, 0.25, 0.5,
1, 2, 3, 4, 5, 6, 9 and 12 h after intravenous injection. All blood
samples were immediately centrifuged at 10,000 rpm for 10 min,
and the plasma was transferred into clean tube and stored at
−80 °C prior to analysis, until analyzed. The pharmacokinetic
parameters were calculated by drug and statistics (DAS) soft-
ware 2.0 (Shanghai, China) pharmacokinetic program.
3. Results and discussion
3.1. Method development
3.1.1. Optimization of chromatographic and mass conditions
In order to optimize MS condition, a standard solution of the
hederasaponin B and IS were directly infused along with the
mobile phase into the mass spectrometer with electrospray ion-
ization (ESI) as the ionization source. Compared with the
response observed in positive ion mode and negative mode,
we discovered that hederasaponin B and IS had stronger signal
intensity and lower background noise in positive ion mode.
Therefore, detection was performed in positive ion mode in
this study. The full-scan ESI-MS (positive ionization mode) of
hederasaponin B and IS showed the protonate molecular ions
[M+Na]+ at m/z 1227.27, and 1097.48, respectively, because of
the good sensitivity, reproducibility and response stability.Thus,
[M+Na]+ were chosen as the precursor ions for MS/MS analy-
sis.The full-scan product ion spectra of analytes were provided
in Fig. 1.
Chromatographic conditions played a critical role in achiev-
ing good chromatographic behavior. In this study, acetonitrile
was chosen as the organic phase because of the advantage of
higher responses and lower background noise by comparison
with methanol. Previous study indicates that low concentra-
tion of acid solution can facilitate the protonation and improve
the intensity of basic compounds in the positive mode [19]. Dif-
ferent concentrations of formic acid (0.05%, 0.1% and 0.2%) were
added to acetonitrile-water as different mobile phases. The
shape of peak and intensities of hederasaponin B and IS were
improved significantly when 0.1% formic acid was added in the
mobile phase. Moreover, isocratic elution was also tested, but
it showed shortcomings of asymmetry peak. Finally, gradient
elution with acetonitrile −0.1% formic acid in water was se-
lected to be the mobile phase. In addition, compared with other
researches [18,20] about constituents similar to hederasaponin
B, our study was less consuming time, only about 4 min.
3.1.2. Optimization of sample preparation
Sample preparation is an important step for accurate and re-
liable UPLC–MS/MS assay. Several sample pre-treatment
methods were investigated in this study, including protein pre-
cipitation and liquid–liquid extraction (LLE). However, the liquid–
liquid extraction with ethyl acetate or n-butanol showed limited
extraction recovery efficiency, considering the polarity of the
analytes. Thus, the protein precipitation method which was
simpler and less time consuming was finally used. Different
precipitation organic solvents (methanol, acetonitrile or acetone)
were evaluated. Results showed that a precipitation with ace-
tonitrile provided a higher recovery and perfect peak shape for
both hederasaponin B and IS.
3.1.3. Selection of internal standard
According to the US Food and Drug Administration (FDA) guid-
ance, any IS used in biological analysis should be a structurally
similar analog of the analytes or a stable labeled compound.
In this study, baicalin, scutellarin and hederacoside D were
tested. However, baicalin or scutellarin were unsatisfactory
choices for the IS, on account of poor peak shape and low re-
sponse.Therefore, hederacoside D was chosen as the IS, because
of the high ionization response in ESI mass spectrometry and
a similar chromatographic retention time.
3.2. Method validation
3.2.1. Specificity
The detection of hederasaponin B and IS by MRM mode was
highly selective with no interference from the endogenous sub-
stances. Fig. 2 represents typical chromatograms of blank
plasma, blank plasma spiked with hederasaponin B at LLOQ
and IS, and rat plasma sample collected after intragastric ad-
ministration of 25 mg/kg hederasaponin B. Typical retention
times for hederasaponin B and IS were 2.08 min and 1.79 min,
respectively.
3.2.2. Linearity and LLOQ
The calibration curves showed good linearity over the con-
centration range of 0.5–5000 ng/ml in rat plasma. A typical
equation of the calibration curves was y = 0.00435x + 0.00231
(r = 0.9928), where y was the peak area ratio of hederasaponin
B to IS and x was the concentration of hederasaponin B. The
LLOQ for hederasaponin B in rat plasma was 0.5 ng/ml and the
result of accuracy and precision were shown in Table 2, which
was sufficient for the pharmacokinetic study. Compared with
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other hederasaponin researches [17,18], our method could obtain
lower LLOQ.
3.2.3. Recovery and matrix effect
As shown in Table 2, the extraction recovery was in the range
of 85.0–91.8% for hederasaponin B, which could meet the re-
quirements of analysis. Results of matrix effects indicated that
no significant matrix effects were observed for the analytes.
3.2.4. Precision and accuracy
The results of intra- and inter-day precision and accuracy at
three concentration levels of the QC samples (1, 100 and
4000 ng/ml) were summarized in Table 2. The intra- and inter-
day RSD were measured to be below 6.3% and 8.4%, and the
RE was within 3.9%. The results demonstrated that both the
intra- and inter-day assay values were all within the accept-
able range.
3.2.5. Stability
The data of stability were summarized in Table 3, which in-
dicated that hederasaponin B had no effect on stability in auto-
sampler (12 h) at 4 °C., at room temperature for 6 h, through
repeated three freeze-thaw cycles and under the frozen con-
dition at −20 °C for two weeks.
3.3. Pharmacokinetic application
The validated UPLC-MS/MS method was successfully applied
to a pharmacokinetic study of hederasaponin B in rats. The
Fig. 2 – Representative MRM chromatograms of IS (A), hederasaponin B (B) in rat plasma: blank rat plasma (I), blank rat
plasma spiked with hederasaponin B at LLOQ and IS (II) and rat plasma samples at 1h after drug administration (III).
Table 2 – Precision, accuracy, recovery and matrix effect of hederasaponin B in rat plasma (n = 6).
Concentration(ng/ml) Intra-day RSD(%) Inter-day RSD(%) Accuracy RE(%) Recovery (%,mean) Matrix effect(%,mean)
0.5 8.1 13.5 −13.7 90.2 104.4
1 6.3 8.4 1.8 85.0 101.7
100 4.9 3.5 3.9 91.8 95.7
4000 3.8 5.1 3.4 89.6 96.8
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mean plasma concentration-time curves of the hederasaponin
B after (A) intragastric administration of 25 mg/kg and (B) in-
travenous administration of 2 mg/kg to rats were shown in
Fig. 3. A non-compartment model was used to calculate the
pharmacokinetic parameters. The pharmacokinetic param-
eters of hedersaponin B in male SD rats were shown in Table 4.
Results showed that hederasaponin B was absorbed very
quickly after intragastric administration, which reached the peak
concentration (Tmax) at 0.633 h. Then, the concentration went
down with an elimination half time (t1/2) of 7.683 h, but at about
5 h, a double-peak phenomenon and “absorption window” were
observed. This phenomenon was similar to some other sa-
ponins [21,22]. It is acceptable that drug absorption may be
affected by membrane permeability, presystemic metabo-
lism, along the gastrointestinal tract, enterohepatic circulation
and variable gastric emptying [23,24].Therefore, further studies
should be carried out to ascertain whether this phenomenon
is related to enterohepatic circulation or other mechanisms.
The absolute bioavailability is one of the most significant
pharmacokinetic parameter for a drug because it is a good
indicator for delivery capability of the drug to systemic circu-
lation. The absolute bioavailability (F) is presented as:
F = (AUCig × Div)/(AUCiv × Dig) × 100%. However, similar to other
saponins, hederasaponin B showed very low oral bioavailability,
only about 0.24 ± 0.49%, which likely resulted from extensive
metabolism in the gastrointestinal tract and the poor intesti-
nal absorption [25,26]. Thus, further studies of distribution,
metabolism, and excretion of hederasaponin B need to be in-
vestigated. In addition, as mentioned above, oral bioavailability
of hederasaponin B was very low, and its concentration in blood
after intravenous injection reduced rapidly. It indicated that
current oral administration and even intravenous injection, are
not very appropriate, and formula modification is necessary.
4. Conclusion
A fast, accurate and sensitive UPLC–MS/MS method was es-
tablished and validated to quantify the concentration of
hederasaponin B in rat plasma for the first time. It had been
successfully applied to the preliminary pharmacokinetic study
of hederasaponin B after intragastric and intravenous admin-
istrations.The absolute bioavailability was calculated to be only
about 0.2%. However, it is worth expecting that metabolic profile
of hederasaponin B and other related investigation will be
Table 3 – Stability of hederasaponin B under various
storage conditions.
Conditions Concentration
(ng/ml)
RSD(%) RE(%)
Room temperature for 6 h 1 9.4 −4.7
100 2.8 2.5
4000 4.1 −1.8
Processed samples in
autosampler for 12 h
1 3.6 1.5
100 5.2 −2.2
4000 2.8 −1.5
Frozen for 2 weeks 1 8.7 −3.1
100 4.6 −1.1
4000 2.4 0.7
Three freeze–thaw cycles 1 9.4 0.5
100 7.2 −1.3
4000 5.4 −3.7
Fig. 3 – Mean plasma concentration–time curves of Hederasaponin B after (A) intragastric administration of 25 mg/kg and
(B) intravenous administration of 2 mg/kg to rats.
Table 4 – Main pharmacokinetic parameters of
hederasaponin B after intragastric administration of
25 mg/kg and intravenous administration of 2 mg/kg to
rats (mean ± SD, n = 5).
Parameters 25 mg/kg(ig) 2 mg/kg(iv)
Cmax(ng/ml) 35.088 ± 14.244 2720.683 ± 416.196
AUC0→t 255.163 ± 154.091 8342.153 ± 2523.868
AUC0→∞ 264.969 ± 152.538 8586.263 ± 2717.299
t1/2 7.683 ± 1.383 2.135 ± 0.354
Tmax 0.633 ± 0.774 0.083 ± 0
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continued. Moreover, the present pharmacokinetic research of
hederasaponin B will provide also helpful information for the
development and reasonable usage of it in the future.
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